Zacks Analyst Blog Highlights: D.R. Horton, Lennar, Weyerhaeuser, Owens Corning and Allergan Inc.

For Immediate Release

Chicago, IL – May 29, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: D.R. Horton (DHI - Analyst Report), Lennar (LEN - Snapshot Report), Weyerhaeuser (WY - Snapshot Report), Owens Corning (OC - Snapshot Report) and Allergan, Inc. (AGN - Analyst Report).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Thursday’s Analyst Blog:

New Home Sales Flat

With interest rates backing up sharply, it appears that the bulk of the work to bring the months of supply back to more normal levels will have to come from further reductions in new housing starts. This is bad news for the homebuilders like D.R. Horton (DHI - Analyst Report) and Lennar (LEN - Snapshot Report) as well as for the suppliers to the homebuilders, including lumber companies like Weyerhaeuser (WY - Snapshot Report) and roofing and insulation suppliers like Owens Corning (OC - Snapshot Report).

Overall however, we have seen worse new housing reports -- "flat" is better than "flattened." Stabilizing at a very low level is better than continuing to plunge. However, I do not see a real recovery in the cards anytime soon.

Allergan Battling Challenges Well

From a fundamental standpoint, we are enthusiastic about the future of Allergan, Inc. (AGN - Analyst Report). Although the company is facing significant challenges in the form of slowing sales due to the global economic weakness, safety issues surrounding the use of Botox and foreign currency headwinds, we think Allergan will be able to face these challenges well and will be back on its historical mid-to-high teens earnings growth trajectory starting in 2011.

We consider Allergan to be one of the premier specialty pharmaceutical companies in the world. The company possesses a strong blockbuster product in Botox and a slew of innovative new products in the eye and skin care markets.

Allergan has also been pretty active on the acquisition front over the past few quarters. We believe these acquisitions will provide the company with the opportunity to drive growth in its existing business and to expand into new areas of business. Even in the face of slowing consumer spending, Allergan’s presence across different segments and geographies should help maintain decent growth going forward.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com